Type I diabetics with microalbuminuria are destined for progressing renal disease. Tolrestat, a new type of aldose reductase inhibitor, may block the glucose to polyol pathway and prevent disorderd phosphoinositide metabolism, which may prevent diabetic renal disease.
Showing the most recent 10 out of 674 publications